April 14, 2021 | Blogs
In this three-part series, CBPartners’ Digital Therapeutics & Health Technology Expertise Team interviews some of the leaders of the digital therapeutics (DTx) space to collect their thoughts on the current challenges and opportunities for DTx commercialization.
November 3, 2020 | Blogs
New cell therapy technologies show blockbuster potential for improved accessibility and efficacy in a wide range of indications, though these therapies come with their own downfalls that healthcare systems will need to adapt to in order for these products to reach their full potential.
October 29, 2020 | Blogs
An analysis of the key drug pricing proposals in the 2020 USA Election in terms of political focus, party priorities, implementation feasibility, and potential risk to biopharma.
October 20, 2020 | Blogs
Pharma and biotech companies should be prepared to make long-term investments in capability building, market development, and evidence generation to maximize the value of digital companions.
September 22, 2020 | Blogs
CAR-Ts offer a significant clinical benefit for patients, however their full potential is currently limited by later line use at sites that are mostly academic centers, combined with significant logistical barriers. In CBPartners’ latest thought leadership article, our healthcare consultants look further into these barriers before assessing the opportunities that could bring CAR-Ts into earlier lines of treatment across oncology.